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Abstract
Background: Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic
hepatocellular carcinoma (EHCC) as well. No report involves a side effect of delayed high fever of sorafenib. This
manuscript describes a case of EHCC in the thoracic and abdominal cavities, who showed a delayed high fever and
maculopapules during sorafenib treatment.
Case presentation: The patient is a 63-year-old Chinese male with advanced EHCC, taking sorafenib 400 mg twice
daily. On the tenth day, red maculopapules appeared all over the body. On the same day, the patient began to suffer
from continuous high fever. Due to these effects, the patient was asked to cease sorafenib treatment, and the high
fever and maculopapules were alleviated quickly. However, the symptoms were present again upon re-challenge of
sorafenib. Prednisone was then administered to control the symptoms, with the dosage gradually reduced from 30 to
5 mg/day in 1.5 months. No recurrence of fever or maculopapules has been found. Tumor response reached partial
response (PR) and progression free survival (PFS) reached 392 days + by the date of Apr. 14th, 2016.
Conclusion: EHCC could be treated like orthotopic HCC by oral administration of sorafenib, which shows good tumor
response and survival benefit. Delayed high fever and maculopapules are potential, rare and severe side effects of
sorafenib, and could be effectively controlled by glucocorticoid.
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Background
Ectopic hepatocellular carcinoma (EHCC) is a rare malig-
nancy from ectopic liver, a kind of developmental abnor-
mality [1–3]. The incidence of ectopic liver is only about
0.27 – 0.7 % [3–5]. However, ectopic liver is more likely to
develop primary hepatocellular carcinoma (HCC) com-
pared with normal liver tissues. Although sorafenib is the
standard first-line therapy for HCC, there is rare report on
the role of sorafenib in treating EHCC [2]. Here we report
a case of EHCC in the thoracic and abdominal cavities,
who interestingly showed symptoms of delayed high fever
and maculopapules during sorafenib treatment.
Case presentation
A 63-year-old male presented with a history of hepatitis B
virus (HBV) infection for 20 years and no anti-HBV treat-
ment. In mid-Jan. 2015, the patient developed progressive
and dull chest pain without obvious inducement. Chest
CT scan revealed multiple pulmonary nodules and
enlarged mediastinal lymph nodes. The level of serum
alpha-fetal protein (AFP) reached 24793 ng/mL. Due to
no hepatic lesion found by contrast abdominal CT and
MRI scan, F-18 positron emission tomography-computed
tomography (PET/CT) was carried out. Unexpectedly,
PET/CT definitely showed that multiple lesions in the thor-
acic and abdominal cavities, including several lung nodules
in the maximum size of 1.7 cm× 1.7 cm (Fig. 1 a1), medias-
tinal lymph nodes in the maximum size of 6.4 cm× 3.2 cm
(Fig. 1 a2), and intraperitoneal mass in the fundus of stom-
ach, cardia, portal fissure and abdominal aortas in the size
of 4.6 cm× 2.2 cm (Fig. 1 a3), but still no hepatic lesion
(Fig. 2a-d). On Mar. 6th, 2015, the patient underwent a
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wedge resection of right pulmonary. The pathological
morphology displayed cancer cell nest with pseudoglandu-
lar structure and focal necrosis area, typical hepatocellular
carcinoma cells with polygonal shape, eosinophilic cyto-
plasm and big anachromasis nucleus. And immunohisto-
chemistry showed the expressions of CK18 ++, Glypican-3
++, Hepatocyte +, P53 + and Ki–67 60 - 70 %, which con-
firmed the diagnosis of primary HCC (Fig. 3 a-f). Thus, the
patient was a rare case of EHCC in an advanced stage.
Following the standard therapy of HCC in National
Comprehensive Cancer Network (NCCN) guidelines [6],
the patient began to take sorafenib 400 mg twice daily
together with Chinese medicines (Jinlong capsule, Jian-
sheng Company, China) and immunopotentiative agents
(ubenimex capsules, Yuandong Company, China) on
Mar. 19th, 2015. On the tenth day (Mar. 28th, 2015), red
maculopapules appeared in the face, neck, abdomen,
back and legs (Fig. 4 a and b). From the same day, the
Fig. 1 Tumor response during sorafenib treatment. PET/CT showed multiple lesions in both lungs (a1), mediastinal lymph nodes (a2) and
abdominal cavity (a3). No lesion was found in the liver by PET/CT (a3), abdominal MRI (d1-d3). The tumor response in both intrathoracic and
intraperitoneal lesions dramatically shrank (b1-b3, c1-c3 and d1-d3)
Fig. 2 No hepatic lesion in PET-CT, abdominal CT and MRI. a-d no hepatic lesion in PET-CT at the beginning. e-f no hepatic lesion in abdominal
CT and MRI at last follow-up one year later
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patient began to suffer from continuous high fever, with
highest body temperature ranging from 39.0 °C to 39.6 °
C each day. The patient did not decrease the dose or
stop the use of sorafenib despite feeling dizzy and fa-
tigue. There was no abnormality in blood routine or
blood culture examination, no pulmonary infection or
other inflammatory signs. After taking non-steroidal
drugs with antipyretic and anti-allergic properties and
withdrawing all drugs except sorafenib, no significant
improvement was observed in high fever and maculopa-
pules. Therefore, the patient was asked to cease the use
of sorafenib from Apr. 3rd, 2015. Strikingly, the high
fever and maculopapules were alleviated quickly. On the
third day, the body temperature returned to the normal
level, and on the fourth day, the maculopapules almost
completely disappeared. Next, the patient began to take
sorafenib again at the standard dose of 400 mg twice
daily on Apr. 7th, 2015. As expected, the fever
Fig. 3 Pathological diagnosis of ectopic hepatocellular carcinoma. a HE staining, cancer cell nest with pseudoglandular structure and focal
necrosis area (100×). b HE staining, morphologically typical hepatocellular carcinoma cells with polygonal shape, eosinophilic cytoplasm and big
anachromasis nucleus. c Ki-67, positive in nucleus (60–70 %, 100×). d CK18, positive on membrane (++, 100×). e Hepatocyte, positive in cytoplasm
(+, 100×). f Glypican-3, positive in cytoplasm (++, 100×)
Fig. 4 Skin reaction all over the body. Red maculopapules in the back and legs (a, b). Hand-foot skin reaction in both hands (c). Rash in the scalp
and ears (d)
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developed, raising the body temperature to 38.1 °C on
exactly the same day, to 38.4 °C the next day and 38.8 °C
the third day. Also, the red maculopapules relapsed at
the same time. Hence, prednisone was administered at a
dosage of 30 mg/day on the fourth day. The body
temperature was decreased and maculopapules relieved
quickly. The dosage of prednisone was gradually reduced
from 30 to 10 mg/day in one month, and then kept at
5 mg/day for another two weeks. After the patient’s
temperature has returned to normal for more than one
month, he intermittently took ubenimex and Jinlong
capsule again. There has been no recurrence of fever
and maculopapule to date. The dynamic change in body
temperature is reflected in Fig. 5a. Other common side
effects also need to be mentioned, such as hand-foot
syndrome and rash in the scalp and ears and body (Fig. 4
c and d). During the follow-up, the tumor response of
both intrathoracic and intraperitoneal lesions reached
partial response (PR) according to RECIST 1.1 criteria.
The lung nodules, mediastinal lymph nodes and intra-
peritoneal mass shrank gradually from Mar. 19, 2015 to
Apr. 12th, 2016 (Fig. 1 b1-b3, c1-c3 and d1-d3), with the
maximum size of 0.8 cm × 0.6 cm, 3.7 cm × 2.2 cm and
2.0 cm × 1.9 cm at the date of Apr. 12th, 2016, respect-
ively. There was still no lesion in liver, revealed by re-
peated examinations of abdominal ultrasound, CT and
MRI (Fig. 2 e and f). In addition, serum AFP gradually
dropped from 24793 ng/mL to 2.19 ng/mL on Apr. 12th,
2016 following the disease control (Fig. 5b). Until Apr.
14th, 2016 in the last review, the patient had maintained
a good condition with progression free survival (PFS) of
392 days + .
Conclusions
Consistent with most HCC in orthotopic liver tissue,
EHCC also arises as a result of chronic hepatitis B or C
infection and secondary cirrhosis [7, 8]. However, many
factors including liver metabolism disorders, damage of
cellular repair, and carcinogen microenvironment, cause
a greatly higher incidence of EHCC than that of orthoto-
pic HCC [1, 4, 7]. The diagnosis of EHCC mainly de-
pends on surgery and pathologic diagnosis, and cannot
be based on serum AFP level and medical history of
hepatitis B virus infection. We report a classical case of
EHCC here. First, this patient suffered from a 20-year
HBV infection and mild hepatocirrhosis. Second, im-
aging techniques showed no tumor in the liver at initial
diagnosis and during the thirteen-month follow-up.
Third, postoperative serum AFP level was more than
16000 ng/ml and dropped dramatically following the dis-
ease control after sorafenib treatment. Last and most
important, pulmonary lobectomy provided the patho-
logic diagnosis of HCC.
Sorafenib is a multi-kinase inhibitor that blocks signal-
ing pathways in tumor growth [9, 10]. In a global clinical
trial of patients with advanced HCC in 2008, the median
overall survival (mOS) in sorafenib group was 2.8 months
longer than that in placebo group (10.7 months vs
7.9 months), and the mPFS in sorafenib group was
2.3 months longer than that in placebo group
(5.5 months vs 2.8 months) [11]. And a phase III, rando-
mised, double-blind, placebo-controlled trial in Asia-
Pacific region in 2009 revealed that mOS was 2.3 months
longer in sorafenib group than in placebo group
(6.5 months vs 4.2 months) [12]. In the current case, the
Fig. 5 Changes in body temperature and AFP. a After ten-day administration of sorafenib, the patient suffered from high fever from Mar. 29th,
2015. Upon cease of sorafenib use on Apr. 3rd, 2015, the high fever decreased quickly. After taking sorafenib again at Apr. 7th, and the fever
developed. After daily administration of prednisone, the body temperature returned to the normal. b The serum AFP gradually dropped from
24793 ng/mL to 2.19 ng/mL from March 16th, 2015 to Apr. 12th, 2016
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patient keeps a good condition with PFS of 392 days+,
which is much longer than that in previous trials [11, 12].
To the best of our knowledge, this is the first case report
that describes sorafenib treatment in a case of EHCC.
Sorafenib also produces adverse effects including skin
toxicity, gastrointestinal reaction, systemic reaction and
vascular dysfunction, hoarseness, fever, pain, ulcers in
the mouth, etc. Hand-foot syndrome and rash are the
most common adverse events. In the Sorafenib Hepato-
cellular Carcinoma Assessment Randomized Protocol
(SHARP) trial, hand-foot skin reaction occurred in up to
21 % of enrolled patients [13]. Sorafenib treatment in
HCC possibly causes rare side effects, such as rhabdo-
myolysis thyroid crisis and liver failure [14–17]. Most
side effects could be alleviated after reducing or ceasing
the use of the drug. To the best of our knowledge, this is
the first case report that describes delayed high fever
and maculopapules during sorafenib treatment as well.
High fever and maculopapules rapidly relieved when
ceasing sorafenib treatment and returned soon after so-
rafenib re-challenging. We propose that the delayed high
fever and maculopapules are potential side effects of so-
rafenib. Additionally, we can exclude the cause of de-
layed high fever in the use of ubenimex and Jinlong
capsule, because we stopped these medicines once the
patient suffered from fever. However, there was no
change in high fever. And when the patient took these
medicine later, there has been no recurrence of fever.
In conclusion, EHCC could be treated like orthotopic
HCC by orally administering sorafenib, and the treat-
ment can achieve good tumor response and survival
benefit. Delayed high fever and maculopapules are po-
tential, rare and severe side effects of sorafenib, which
could be effectively controlled by glucocorticoid.
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